Because the regrowth of cancer cells between cycles of cytoreduction is likely to be more rapid in HER2 + tumours, the more frequent administration of anthracycline-containing chemotherapy could be particularly effective in these anthracycline-sensitive tumours. The gene discussed is ERBB2; the disease is neoplasm.